World EPA Congress Europe 2027
2 March 2027 – 3 March 2027
RAI Amsterdam, Amsterdam, Netherlands
The World Evidence, Pricing and Access Congress (World EPA Congress) Europe is a two-day congress organised by Terrapinn at the RAI Congress Centre in Amsterdam, covering market access, pricing, reimbursement, rare diseases, health technology assessment, and health economics and outcomes research in healthcare. The 2027 edition is billed as featuring around 250 speakers across 10 tracks, more than 1,600 attendees from pharma, biotech and payer/HTA organisations, an exhibition of 120+ solution providers and built-in one-to-one networking.
123 sessions · 147 speakers
Organiser (1)
Sponsors (4)
Acumetis · Charles River Assoctiates · Elicit · Propharma group
Exhibitors (3)
WEP CLINICAL · Pharos Labs · Accuscript
Supporting Partners (5)
Biopharma Asia · BioPartner U.K. Ltd · NAVLIN Daily by Eversana · fondazione telethon · PharmaVision
Agenda
- Chair's opening remarks 2 March 2027
- Implications of policy changes on market access 2 March 2027
- Keynote panel: The future of European JCA: From Joint Assessments to National Access 2 March 2027
- Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC 2 March 2027
- Keynote: Access by design: Embedding access into core development decisions - TBC 2 March 2027
- Chair's opening remarks 2 March 2027 · Track 4
- Chair's opening remarks 2 March 2027 · Track 6
- Chair's opening remarks 2 March 2027
- Chair's opening remarks 2 March 2027
- Chair's opening remarks 2 March 2027
- Chair's opening remarks 2 March 2027
- Chair's opening remarks 2 March 2027 · Track 1
- Chair's opening remarks 2 March 2027 · Track 2
- Chair's opening remarks 2 March 2027 · Track 3
- Most favoured nations, least favoured patients? How US pricing policy could reshape global health equity - TBC 2 March 2027
- Actionable Frameworks for Rapid Market Access Planning 2 March 2027
- AI will decide who gets access: why drug contracting is becoming pharma’s most strategic capability - TBC 2 March 2027
- Anchoring evidence-based decisions in a volatile policy landscape: strategic considerations for EU HTAR - TBC 2 March 2027
- CAR-T's Second Act: Reimagining Cell Therapy for the Next Decade 2 March 2027
- Clearing the fog: A practical guide to EUHTA JCA & expected Country P&R Processes - TBC 2 March 2027
- Quantifying patient flow and costs in rare disease – Benefits for all - TBC 2 March 2027
- From JSC to HTA: early decisions that shape price and access success 2 March 2027
- Human-in-the-Loop, Generative AI for Joint Clinical Assessment: From PICO Simulations and Living Systematic Literature Reviews to Submission ready JCA Dossiers 2 March 2027
- Biosimilar-Enabled Access Repositioning: how to extract more value for patients and health systems 2 March 2027
- Sustainability in reimbursement decisions 2 March 2027
- Critical Medicines Act and Recent Policy Changes 2 March 2027
- When Geopolitics Sets the Price: Rethinking HTA’s Value Lens to Sustain Pharmaceutical Innovation in Europe 2 March 2027
- The Role of AI in HTA: Perspectives from the HTAi AI & Data Interest Group 2 March 2027
- Real World Evidence to Demonstrate Value in Mental Health Treatments 2 March 2027
- Results from CAPRICORD - Poland HTA and Patient Involvement - TBC 2 March 2027
- Agility to Enhance Payer Engagement Using AI 2 March 2027
- Navigating Market Access & Joint Clinical Assessment (JCA) 2 March 2027
- Beyond the Surrogate: What European Payers Taught Us About Launching a Rare Disease Therapy 2 March 2027
- Beyond advocacy: a multi-stakeholder panel on patient-informed HTA & economic models - TBC 2 March 2027
- Access starts early: Integrating regulatory and market access to accelerate launch and reduce risk 2 March 2027
- How AI Is Reshaping JCA Preparation 2 March 2027 · Track 8
- Designing Reimbursement Frameworks That Match Evolving Payer Thresholds - TBC 2 March 2027
- Policy, pricing, and power shifts: how EU, UK, and global policies are reshaping pharma market access - TBC 2 March 2027
- Strategic Evidence Generation in Oncology - TBC 2 March 2027 · Track 9
- Building innovative medicines access capabilities within a historically generics-focused organization 2 March 2027 · Track 1
- AI, Avatars, and Access: Revolutionizing Patient Engagement and Real-World Evidence 2 March 2027
- Mind the Gap: evidence requirements for regulatory, evaluation and adoption - TBC 2 March 2027
- Novel types of evidence: can they support reliable HTA decisions? 2 March 2027 · Track 5
- The missing middle in market access & bridging global strategy with local execution 2 March 2027 · Track 4
- Reimbursement in China: latest updates 2 March 2027 · Track 6
- Rethinking Pharma Pricing: Budget Pressures, Value Promises, and Gulf Policy Shifts 2 March 2027
- Retrospective Data as a Proof of Concept for Future Healthcare Sustainability - TBC 2 March 2027
- Meaningful patient involvement to improve equity in HTA 2 March 2027
- Financing Innovation: Next-generation reimbursement models 2 March 2027
- Market Access Under Pressure: Practical Solutions to Global Policy Shifts like MFN 2 March 2027
- From Advice to Access: The Role of JSCs in National Pricing and Reimbursement Success 2 March 2027
- From silos to systems: HTA & Pharmaceutical companies & The Trump effect in an ever-changing world - TBC 2 March 2027
- Pre-launch success for orphan diseases in the JCA era - TBC 2 March 2027
- AI & Digitalization in HTA: Regulation, Transparency and Value 2 March 2027
- Launching Rare Disease Therapies in Europe and Globally: Aligning Evidence, Pricing, and Access from Day One 2 March 2027
- Title TBC 2 March 2027
- Chair's remarks 2 March 2027
- Chair's remarks 2 March 2027 · Track 3
- Chair's remarks 2 March 2027 · Track 4
- Chair's remarks 2 March 2027
- Track Chair 2 March 2027 · Track 2
- Chair's opening remarks 2 March 2027 · Track 6
- Chair's opening remarks 2 March 2027
- Chair's opening remarks 2 March 2027
- Chair's remarks 2 March 2027
- Trends in HTA and the new launch sequence: market prioritization in a world of changing policies - TBC 2 March 2027
- Factors impacting GKV rebates for orphan drugs (OD) and the evolution of OD pricing in Germany - TBC 2 March 2027
- The only way is down? Sustaining value through indication expansion - TBC 2 March 2027
- Europe still Under MFN Pressure: Reading Pricing and Reimbursement Signals and Launch Implications 2 March 2027 · Track 3
- The future of HEOR in HTA: what you need to start doing NOW for improved market access - TBC 2 March 2027
- Deeper payer insights when you need it: How rapid payer research can elevate your market access playbook - TBC 2 March 2027
- How to generate robust RWE to inform HTA/Payer Decision-Making 2 March 2027 · Track 5
- No Green, No Go: How Sustainability is Shifting from a Corporate Responsibility to a Hard Payer Criterion 2 March 2027
- Pricing & reimbursement in an MFN era 2 March 2027
- Germany's new reimbursement policies and the impact on markets 2 March 2027
- Policy change impacts on pricing & access of rare disease treatments beyond Europe and US - TBC 2 March 2027
- Health Technology Assessment and Real-World Uptake in Denmark - TBC 2 March 2027
- AI in Market Access 2 March 2027
- Title TBC 2 March 2027 · Track 9
- HTA approval is not the End of Market Access: The Road to Sustainable Access is a Marathon, not a Sprint 2 March 2027 · Track 4